Hypophosphatasia

Overview

Hypophosphatasia (HPP) is a rare inherited metabolic disorder caused by disease-causing variants in the ALPL gene, which lowers the activity of tissue-nonspecific alkaline phosphatase (TNSALP). Low TNSALP allows substances including inorganic pyrophosphate (PPi), a natural inhibitor of mineral formation, to accumulate; this can impair development and maintenance of bones and teeth and affect vitamin B6 metabolism. Diagnosis and treatment of HPP HPP affects people across the lifespan, ranging from life-threatening disease before or soon after birth to childhood rickets, premature tooth loss, recurrent fractures, pain, weakness, and milder adult presentations. Clinical practice guidelines

Prognosis depends greatly on age of onset and severity. Untreated severe perinatal and infantile HPP can be fatal, whereas adults may have chronic and sometimes disabling skeletal, dental, muscular, and pain-related complications. Diagnosis, treatment, and follow-up The current disease-specific standard of care is asfotase alfa, a bone-targeted recombinant TNSALP enzyme replacement therapy, alongside multidisciplinary dental, orthopedic, respiratory, neurologic, rehabilitation, and pain care. It can substantially improve survival and skeletal outcomes in severe pediatric-onset disease, but it does not repair the underlying ALPL variant and is therefore not a genetic cure. Asfotase alfa systematic review

Scope of Recent Research (2020–present)

Research since 2020 has been active but remains small relative to more common genetic diseases. The central questions are whether continuous replacement of alkaline phosphatase can be made less burdensome, whether a one-time gene-delivery treatment can provide lasting enzyme activity, and whether newer cellular engineering platforms can deliver TNSALP safely and durably. AAV8 gene therapy in mice BE-102 pipeline The field is not yet close to a proven curative therapy in people: the most directly curative strategies—gene and engineered-cell approaches—remain preclinical as of October 18, 2026. ARU-2801 program

Major Breakthroughs and Emerging Therapies

The leading potential curative strategy is in vivo gene therapy: delivering a functional alkaline-phosphatase gene so the body can produce its own enzyme after a single treatment. In a 2021 study, a single intramuscular dose of an adeno-associated virus serotype 8 vector carrying a mineral-targeted TNSALP construct, AAV8-TNAP-D10 (also called ARU-2801), increased alkaline-phosphatase activity, reduced PPi, extended survival, and largely corrected rickets-like skeletal and dental defects in newborn Alpl knockout mice, a model of severe infantile HPP. AAV8 gene therapy in mice A separate 2021 report found that a single neonatal muscle injection maintained high plasma enzyme activity for up to 18 months and promoted mature bone mineralization in HPP-model mice. Long-term AAV8 treatment in mice These are important proof-of-concept findings because muscle can function as a factory that releases TNSALP into the bloodstream, potentially avoiding lifelong frequent injections.

However, the mouse results also show why “correction” is not yet synonymous with cure. In the 2021 AAV8 study, treated mice had residual small bone-microstructure defects and somewhat reduced molar enamel and alveolar-bone density despite major improvement in survival and mineralization. AAV8 gene therapy in mice Japanese investigators at Nippon Medical School continue to develop ARU-2801 and report preclinical work spanning infantile and adult-model mice as well as non-human primates, but no human efficacy results have been reported. ARU-2801 program

A second emerging strategy is engineered B-cell therapy. Be Biopharma’s preclinical candidate BE-102 uses CRISPR/Cas9 editing to insert an alkaline-phosphatase expression cassette into human B cells, which are then designed to secrete active TNSALP. In reported laboratory studies, engineered B cells produced active alkaline phosphatase and improved mineralization in an osteoblast precursor-cell model. Engineered B-cell data BE-102 was selected as a development candidate in 2024 and remains in the preclinical stage; its theoretical advantages are sustained protein production, potential redosing, and avoiding permanent direct editing of a patient’s bone cells. BE-102 pipeline

Other work is exploring biological mechanisms that could complement enzyme replacement rather than correct ALPL itself. A 2020 mouse and cell study found that the calcium ionophore ionomycin improved bone-forming-cell behavior and reduced osteoporotic features in Alpl-deficient mouse models, suggesting that altered calcium signaling may contribute to HPP bone pathology. Ionomycin study This remains experimental preclinical biology, not a clinical treatment or a cure.

Clinical Trials and Experimental Approaches

The most advanced recent clinical programs are improved enzyme replacement therapies, which may reduce treatment burden but are not curative. Alexion/AstraZeneca’s efzimfotase alfa (ALXN1850) is a second-generation, bone-targeted TNSALP replacement designed for dosing every two weeks. In a Phase 1 study of 15 adults, efzimfotase alfa showed acceptable short-term safety and dose-related reductions in PPi and pyridoxal-5′-phosphate (PLP), both biochemical markers of deficient TNSALP activity. Efzimfotase Phase 1 Its Phase 3 program includes pediatric treatment-naïve participants in MULBERRY (NCT06079359), previously treated pediatric participants in CHESTNUT (NCT06079372), and treatment-naïve adolescents and adults in HICKORY (NCT06079281).

Company-reported Phase 3 results released in 2026 found that MULBERRY met its bone-health endpoint in children aged 2 to under 12 years, with a median 1.67-point advantage over placebo on the Radiographic Global Impression of Change score at week 25. MULBERRY Phase 3 results In contrast, HICKORY did not achieve statistical significance for its primary six-minute-walk-test endpoint in treatment-naïve adolescents and adults, although numerical improvements favored treatment and some secondary and subgroup analyses were positive. HICKORY Phase 3 results CHESTNUT was reported to show safety, tolerability, and maintenance of therapeutic benefit in children switching from asfotase alfa. Efzimfotase Phase 3 program update

AM-Pharma completed a small Phase 1b/2 pilot trial of intravenous ilofotase alfa in 12 adults with genetically confirmed HPP. A single dose produced dose-dependent, temporary reductions in PPi, PLP, and phosphoethanolamine, with only mild treatment-emergent adverse events reported; the study was designed primarily to test biomarkers and short-term safety rather than fractures, function, or cure. Ilofotase Phase 1b study NCT05890794

Methodologies and Scientific Approaches

Researchers use several complementary models because HPP affects bone, teeth, muscle, and other systems. Severe Alpl knockout mice are used to test whether treatment restores survival, blood alkaline-phosphatase activity, PPi concentrations, skeletal mineralization, and dental attachment; common readouts include radiographs, micro-computed tomography, tissue microscopy, and biochemical markers such as PPi and PLP. AAV8 gene therapy in mice Clinical enzyme-replacement studies similarly use circulating PPi and PLP as pharmacodynamic indicators that administered enzyme is acting on its relevant substrates. Ilofotase Phase 1b study

Larger and more human-like models are also becoming important. A 2022 CRISPR-engineered sheep model carrying an HPP-associated ALPL mutation reproduced key dental and jaw-bone abnormalities, including defective dentin and cementum, premature tooth loss, and low alkaline-phosphatase-associated mineralization changes. HPP sheep model This platform may be especially useful for testing long-term effects on teeth, craniofacial bone, muscle, breathing, and delivery systems that cannot be fully assessed in mice. NIH sheep respiratory project

Leading Institutions and Funding

Important academic contributors include Sanford Burnham Prebys Medical Discovery Institute, Nippon Medical School, and The Ohio State University, whose investigators collaborated on the 2021 AAV8-TNAP-D10 mouse study. AAV8 gene therapy in mice Texas A&M University and Ohio State researchers developed and characterized the translational sheep model, while the National Institutes of Health has supported respiratory research using that model. HPP sheep model NIH sheep respiratory project Nippon Medical School’s gene-therapy group is developing ARU-2801, and Japan’s Agency for Medical Research and Development has highlighted HPP gene therapy within its regenerative medicine and cell/gene therapy programs. AMED cell and gene therapy programs

Industry leadership includes Alexion/AstraZeneca for efzimfotase alfa, AM-Pharma for ilofotase alfa, and Be Biopharma for the preclinical BE-102 engineered B-cell program. Efzimfotase Phase 1 NCT05890794 BE-102 pipeline Patient-led funding also remains meaningful in this ultra-rare disease: Soft Bones, the U.S. HPP Foundation, offers a $25,000 annual seed grant and reports more than $500,000 awarded for HPP research since 2014. Soft Bones research program

Strengths, Limitations, and Challenges

The strongest evidence in HPP is for replacement of missing enzyme activity. Asfotase alfa has transformed outcomes in severe pediatric-onset disease, and the newer efzimfotase and ilofotase studies show that biochemical correction can be achieved with alternative enzyme designs and schedules. Asfotase alfa systematic review Efzimfotase Phase 1 Ilofotase Phase 1b study The AAV8 studies are particularly encouraging because one administration improved survival, bone, and dental disease in mice while producing persistent enzyme activity. Long-term AAV8 treatment in mice

The central limitation is that successful animal rescue has not yet established safety, dose control, durability, or clinical benefit in people. AAV treatment must be shown to deliver enough enzyme for years without unacceptable immune, organ, or off-target mineralization effects, and it may be difficult to adjust or reverse after dosing. AAV8 gene therapy in mice HPP’s marked variability also complicates trials: a treatment can improve pediatric bone radiographs yet have less clear effects on adult mobility, fatigue, pain, or fractures, as illustrated by the HICKORY primary-endpoint result. HICKORY Phase 3 results

Outlook and Future Directions

As of October 18, 2026, HPP is closer to more flexible and potentially more effective enzyme replacement than to a demonstrated one-time cure. The most important milestones to watch are transition of ARU-2801 from animal studies into a regulated human trial, further safety and durability data for BE-102 and other engineered-cell approaches, and peer-reviewed full Phase 3 results for efzimfotase alfa. ARU-2801 program BE-102 pipeline A true cure would need to provide durable, appropriately targeted TNSALP activity that prevents or reverses multisystem disease while remaining safe and accessible across the broad spectrum of HPP.

References

• Diagnosis and treatment of HPP — PubMed, 2025.
• Clinical practice guidelines — Michigami et al., 2020.
• Diagnosis, treatment, and follow-up — Cárdenas-Aguilera et al., 2025.
• Asfotase alfa systematic review — Shirinezhad et al., 2024.
• AAV8 gene therapy in mice — Kinoshita et al., 2021.
• Long-term AAV8 treatment in mice — Matsumoto et al., 2021.
• ARU-2801 program — Nippon Medical School Department of Gene Therapy, 2026.
• Engineered B-cell data — Be Biopharma, 2024.
• BE-102 pipeline — Be Biopharma, 2026.
• Ionomycin study — Jin et al., 2020.
• Efzimfotase Phase 1 — Dahir et al., 2024.
• NCT06079359 — ClinicalTrials.gov, 2026.
• NCT06079372 — ClinicalTrials.gov, 2026.
• NCT06079281 — ClinicalTrials.gov, 2026.
• MULBERRY Phase 3 results — AstraZeneca, 2026.
• HICKORY Phase 3 results — AstraZeneca, 2026.
• Efzimfotase Phase 3 program update — AstraZeneca, 2026.
• Ilofotase Phase 1b study — Seefried et al., 2026.
• NCT05890794 — ClinicalTrials.gov, 2025.
• HPP sheep model — Mohamed et al., 2022.
• NIH sheep respiratory project — National Institutes of Health RePORTER, 2025.
• AMED cell and gene therapy programs — Japan Agency for Medical Research and Development, 2026.
• Soft Bones research program — Soft Bones, 2026.